In a news release, NRx Pharmaceuticals said that it has submitted an application for EUA to the FDA for the use of its drug Zyesami. The company developed it for patients with Covid-19 who are at ...
GENEVA, SWITZERLAND / ACCESSWIRE / May 1, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
GENEVA and RADNOR, Pa., Oct. 13, 2020 /PRNewswire/ -- RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., today announced topline results from 45 ...
GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA RLFRLFTFRLFTY (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, ...
Relief now has Orphan Drug Designations for Its Sarcoidosis, Epidermolysis Bullosa (EB) and Phenylketonuria (PKU) Product Candidates RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ...
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results